MiNK Therapeutics (INKT) has been awarded a grant from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health. The grant will support development of MiNK’s allo-iNKT cell therapy platform for the prevention and treatment of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation, in collaboration with the University of Wisconsin.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics Reports Q1 2025 Progress and Financials
- Mink Therapeutics’ Earnings Call Highlights Progress and Optimism
- Positive Outlook for MiNK Therapeutics: Promising Clinical Developments and Financial Performance
- MiNK Therapeutics: Promising Clinical Trials and Strategic Plans Justify Buy Rating
- MiNK Therapeutics reports Q1 EPS (70c) vs ($1.10) last year